Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890947050> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2890947050 abstract "e20544 Background: The aim of this study was to compare the efficacy and toxicity of gefitinib as first or second line therapy for advanced non-small cell lung cancer (NSCLC) patients with positive exon 21 (L858R) or exon 19 deletion mutation. Methods: We retrospectively analyzed the clinical data of 60 endothelial growth factor receptor ( EGFR) mutated advanced lung adenocarcinoma patients from July 2011 to November 2015, who have received oral gefitinib 250 mg once daily. Gefitinib was taken until disease progression, intolerable toxicity or death. Results: At the time of last follow-up visit, 1 death had occurred. Among the 59 patients who remained survival, 17 patients progressed. Overall, the median progression-free survival (mPFS) was 10 months (95% confidence interval (CI): 7.53–12.46 months, p < 0.05). The response rate (RR) and disease control rate (DCR) were 33.33% and 71.66%, respectively. However, there was longer mPFS in first line therapy than that in second line therapy: in first-line gefitinib therapy, mPFS was 12 months among 41 patients (95% CI: 9.58–14.41 months, p < 0.05); in the second line therapy, mPFS was 7 months among 19 patients (95% CI: 1.31–12.68 months, p < 0.05). Furthermore, in subgroup analyses examining different EGFR mutation types, we noted mPFS was significantly longer for patient with exon 19 deletion than that with positive exon 21in both first line therapy and second line therapy. The most common Grade 1 or 2 adverse events included rash (76.6%), abnormal liver function (60%), dry skin (48.3%), diarrhoea (46.6%), fatigue (40%) and paronychia (33.3%) etcetera in non-haematological toxicity, whereas anemia(33.3%), leukocytopenia (20%) etcetera were included in haematological toxicity. Conclusions: Patients with NSCLC who were selected by positive exon 21 or 19 deletion mutations had significantly longer mPFS in first line therapy than that in second line therapy when treated with gefitinib. And EGFR mutation types may influence the response to gefitinib therapy." @default.
- W2890947050 created "2018-09-27" @default.
- W2890947050 creator A5030277492 @default.
- W2890947050 creator A5080085859 @default.
- W2890947050 creator A5088291390 @default.
- W2890947050 date "2017-05-20" @default.
- W2890947050 modified "2023-09-26" @default.
- W2890947050 title "A comparison of gefitinib for advanced non-small cell lung cancer patients with different EGFR mutation types." @default.
- W2890947050 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e20544" @default.
- W2890947050 hasPublicationYear "2017" @default.
- W2890947050 type Work @default.
- W2890947050 sameAs 2890947050 @default.
- W2890947050 citedByCount "0" @default.
- W2890947050 crossrefType "journal-article" @default.
- W2890947050 hasAuthorship W2890947050A5030277492 @default.
- W2890947050 hasAuthorship W2890947050A5080085859 @default.
- W2890947050 hasAuthorship W2890947050A5088291390 @default.
- W2890947050 hasConcept C104317684 @default.
- W2890947050 hasConcept C121608353 @default.
- W2890947050 hasConcept C126322002 @default.
- W2890947050 hasConcept C143998085 @default.
- W2890947050 hasConcept C2776256026 @default.
- W2890947050 hasConcept C2777714996 @default.
- W2890947050 hasConcept C2779438470 @default.
- W2890947050 hasConcept C2780580887 @default.
- W2890947050 hasConcept C29730261 @default.
- W2890947050 hasConcept C501734568 @default.
- W2890947050 hasConcept C502942594 @default.
- W2890947050 hasConcept C54355233 @default.
- W2890947050 hasConcept C71924100 @default.
- W2890947050 hasConcept C86803240 @default.
- W2890947050 hasConceptScore W2890947050C104317684 @default.
- W2890947050 hasConceptScore W2890947050C121608353 @default.
- W2890947050 hasConceptScore W2890947050C126322002 @default.
- W2890947050 hasConceptScore W2890947050C143998085 @default.
- W2890947050 hasConceptScore W2890947050C2776256026 @default.
- W2890947050 hasConceptScore W2890947050C2777714996 @default.
- W2890947050 hasConceptScore W2890947050C2779438470 @default.
- W2890947050 hasConceptScore W2890947050C2780580887 @default.
- W2890947050 hasConceptScore W2890947050C29730261 @default.
- W2890947050 hasConceptScore W2890947050C501734568 @default.
- W2890947050 hasConceptScore W2890947050C502942594 @default.
- W2890947050 hasConceptScore W2890947050C54355233 @default.
- W2890947050 hasConceptScore W2890947050C71924100 @default.
- W2890947050 hasConceptScore W2890947050C86803240 @default.
- W2890947050 hasLocation W28909470501 @default.
- W2890947050 hasOpenAccess W2890947050 @default.
- W2890947050 hasPrimaryLocation W28909470501 @default.
- W2890947050 hasRelatedWork W2061243857 @default.
- W2890947050 hasRelatedWork W2065543621 @default.
- W2890947050 hasRelatedWork W2113451729 @default.
- W2890947050 hasRelatedWork W2154302986 @default.
- W2890947050 hasRelatedWork W2261901203 @default.
- W2890947050 hasRelatedWork W2283855024 @default.
- W2890947050 hasRelatedWork W2324892749 @default.
- W2890947050 hasRelatedWork W2510052091 @default.
- W2890947050 hasRelatedWork W2513934852 @default.
- W2890947050 hasRelatedWork W2563308044 @default.
- W2890947050 hasRelatedWork W2574173779 @default.
- W2890947050 hasRelatedWork W2589252540 @default.
- W2890947050 hasRelatedWork W2589606748 @default.
- W2890947050 hasRelatedWork W2809065633 @default.
- W2890947050 hasRelatedWork W2981359843 @default.
- W2890947050 hasRelatedWork W2999991955 @default.
- W2890947050 hasRelatedWork W3010926306 @default.
- W2890947050 hasRelatedWork W302287699 @default.
- W2890947050 hasRelatedWork W3131335352 @default.
- W2890947050 hasRelatedWork W2311778681 @default.
- W2890947050 isParatext "false" @default.
- W2890947050 isRetracted "false" @default.
- W2890947050 magId "2890947050" @default.
- W2890947050 workType "article" @default.